PL1797037T3 - Sposób otrzymywania 4-{4-[({[4-chloro-3-(trifluorometylo)-fenylo]amino}karbonylo)amino]fenoksy}-N-metylopirydyno-2-karboksyamidu - Google Patents

Sposób otrzymywania 4-{4-[({[4-chloro-3-(trifluorometylo)-fenylo]amino}karbonylo)amino]fenoksy}-N-metylopirydyno-2-karboksyamidu

Info

Publication number: PL1797037T3
Authority: PL; Poland
Prior art keywords: amino; phenyoxy; methylpyridine; carboxamide; trifluoromethyl
Prior art date: 2004-09-29

Application number

PL05794785T

Other languages

English (en)

Inventor

Michael Lögers

Reinhold Gehring

Oliver Kuhn

Mike Matthäus

Klaus Mohrs

Matthias Müller-Gliemann

Jürgen Stiehl

Mathias Berwe

Jana Lenz

Werner Heilmann

Original Assignee

Bayer Healthcare Llc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-09-29

Filing date

2005-09-20

Publication date

2015-07-31

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35457568&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL1797037(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2005-09-20 Application filed by Bayer Healthcare Llc filed Critical Bayer Healthcare Llc

2015-07-31 Publication of PL1797037T3 publication Critical patent/PL1797037T3/pl

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Epidemiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Pyridine Compounds (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Coloring Foods And Improving Nutritive Qualities (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines Containing Plant Substances (AREA)
Developing Agents For Electrophotography (AREA)

PL05794785T 2004-09-29 2005-09-20 Sposób otrzymywania 4-{4-[({[4-chloro-3-(trifluorometylo)-fenylo]amino}karbonylo)amino]fenoksy}-N-metylopirydyno-2-karboksyamidu PL1797037T3 (pl)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
EP04023131		2004-09-29
EP05794785.5A EP1797037B1 (en)	2004-09-29	2005-09-20	Process for the preparation of 4-{4-[({[4-chloro-3-(trifluoromethyl)phenyl]amino}carbonyl)amino]phenyoxy}n-methylpyridine-2-carboxamide
PCT/EP2005/010118 WO2006034796A1 (en)	2004-09-29	2005-09-20	Process for the preparation of 4-{4-[({[4-chloro-3-(trifluoromethyl)phenyl]amino}carbonyl)amino]phenoxy}-n-methylpyridine-2-carboxamide

Publications (1)

Publication Number	Publication Date
PL1797037T3 true PL1797037T3 (pl)	2015-07-31

Family

ID=35457568

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL05794785T PL1797037T3 (pl)	2004-09-29	2005-09-20	Sposób otrzymywania 4-{4-[({[4-chloro-3-(trifluorometylo)-fenylo]amino}karbonylo)amino]fenoksy}-N-metylopirydyno-2-karboksyamidu

Country Status (35)

Country	Link
US (1)	US8124782B2 (pl)
EP (1)	EP1797037B1 (pl)
JP (2)	JP2008514657A (pl)
KR (1)	KR101263032B1 (pl)
CN (1)	CN101052619B (pl)
AR (1)	AR053973A1 (pl)
AU (1)	AU2005289099B2 (pl)
BR (1)	BRPI0515944B1 (pl)
CA (1)	CA2581835C (pl)
CU (1)	CU23754B7 (pl)
CY (1)	CY1116126T1 (pl)
DK (1)	DK1797037T3 (pl)
DO (1)	DOP2005000183A (pl)
EC (1)	ECSP077357A (pl)
ES (1)	ES2532377T3 (pl)
GT (1)	GT200500269A (pl)
HK (1)	HK1113484A1 (pl)
HN (1)	HN2005000768A (pl)
HR (1)	HRP20150295T1 (pl)
IL (1)	IL182046A0 (pl)
MA (1)	MA28883B1 (pl)
MY (1)	MY149873A (pl)
NO (1)	NO339647B1 (pl)
NZ (1)	NZ554119A (pl)
PE (5)	PE20091585A1 (pl)
PL (1)	PL1797037T3 (pl)
PT (1)	PT1797037E (pl)
SG (1)	SG155997A1 (pl)
SI (1)	SI1797037T1 (pl)
SV (1)	SV2006002243A (pl)
TW (1)	TWI382973B (pl)
UA (1)	UA90691C2 (pl)
UY (1)	UY29143A1 (pl)
WO (1)	WO2006034796A1 (pl)
ZA (1)	ZA200702511B (pl)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ATE556713T1 (de)	1999-01-13	2012-05-15	Bayer Healthcare Llc	Omega-carboxyarylsubstituierte-diphenyl- harnstoffe als p38-kinasehemmer
US8124630B2 (en)	1999-01-13	2012-02-28	Bayer Healthcare Llc	ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
US7838541B2 (en)	2002-02-11	2010-11-23	Bayer Healthcare, Llc	Aryl ureas with angiogenesis inhibiting activity
PT1626714E (pt)	2003-05-20	2007-08-24	Bayer Pharmaceuticals Corp	Diarilureias para doenças mediadas por pdgfr
BR122016015715B8 (pt)	2003-07-23	2021-05-25	Bayer Healthcare Llc	composições farmacêuticas de metilamida de ácido 4[4-[3-(4-cloro-3-trifluorometilfenil)-ureido]-3-fluorofenóxi)-piridina-2-carboxílico
NZ554119A (en)	2004-09-29	2010-07-30	Bayer Schering Pharma Ag	Process for the preparation of 4-{4-[({[4-chloro-3-(trifluoromethyl)phenyl]amino}carbonyl)amino]phenoxy}-N-methylpyridine-2-carboxamide
CA2581843C (en) *	2004-09-29	2012-05-15	Bayer Healthcare Ag	Thermodynamically stable form of bay 43-9006 tosylate
PL1868579T3 (pl)	2005-03-07	2011-03-31	Bayer Healthcare Llc	Kompozycja farmaceutyczna zawierająca difenylomocznik podstawiony omega-karboksyarylem do leczenia nowotworu
AR062927A1 (es) *	2006-10-11	2008-12-17	Bayer Healthcare Ag	4- [4-( [ [ 4- cloro-3-( trifluorometil) fenil) carbamoil] amino] -3- fluorofenoxi) -n- metilpiridin-2- carboxamida monohidratada
JP2010509382A (ja) *	2006-11-14	2010-03-25	バイエル・シェーリング・ファルマ・アクチェンゲゼルシャフト	４−［４−（｛［４−クロロ−３−（トリフルオロメチル）フェニル］カルバモイル｝アミノ）−３−フルオロフェノキシ］−ｎ−メチルピリジン−２−カルボキサミドの多形ｉｉ
WO2009034308A2 (en)	2007-09-10	2009-03-19	Cipla Limited	Process for the preparation of a raf kinase inhibitor and intermediates for use in the process
WO2009054004A2 (en) *	2007-10-22	2009-04-30	Natco Pharma Limited	Process for the preparation of sorafenib
EP2231612A1 (en)	2008-01-17	2010-09-29	Sicor, Inc.	Polymorph form iii of sorafenib tosylate, sorafenib tosylate methanol solvate and sorafenib tosylate ethanol solvate, and processes for preparation thereof
EP2142507A1 (en) *	2008-03-06	2010-01-13	Sicor, Inc.	Process for the preparation of sorafenib and salts thereof
CN103254126A (zh) *	2008-09-19	2013-08-21	苏州泽璟生物制药有限公司	氘代的ω-二苯基脲及衍生物以及包含该化合物的药物组合物
WO2011036647A1 (en)	2009-09-24	2011-03-31	Ranbaxy Laboratories Limited	Process for the preparation of sorafenib tosylate
CA2775296A1 (en)	2009-09-24	2011-03-31	Ranbaxy Laboratories Limited	Polymorphs of sorafenib acid addition salts
US8552197B2 (en) *	2009-11-12	2013-10-08	Ranbaxy Laboratories Limited	Sorafenib ethylsulfonate salt, process for preparation and use
WO2011076711A2 (en)	2009-12-23	2011-06-30	Ratiopharm Gmbh	Polymorphs of 4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-n-methylpyridine-2-carboxamide
WO2011092663A2 (en)	2010-01-29	2011-08-04	Ranbaxy Laboratories Limited	4-(4-{3-[4-chloro-3-(trifluoromethyl)phenyl]ureido}phenoxy)-n2-methylpyridine-2-carboxamide dimethyl sulphoxide solvate
CN102190616B (zh) *	2010-03-18	2015-07-29	苏州泽璟生物制药有限公司	一种氘代的ω-二苯基脲的合成及生产的方法和工艺
AR081060A1 (es)	2010-04-15	2012-06-06	Bayer Schering Pharma Ag	Procedimiento para preparar 4-{4-[({[4-cloro-3-(trifluorometil)fenil]amino}carbonil)amino]-3-fluorofenoxi}-n-metilpiridin-2-carboxamida
CN102617458A (zh) *	2010-05-18	2012-08-01	张南	抗癌用化合物的制备方法
CA2805874A1 (en)	2010-07-19	2012-01-26	Bayer Healthcare Llc	Drug combinations with fluoro-substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions
UA112163C2 (uk)	2010-10-01	2016-08-10	Байєр Інтеллектуал Проперті Гмбх	Комбінації, які містять заміщений n-(2-ариламіно)арилсульфонамід
WO2012071425A1 (en)	2010-11-22	2012-05-31	Teva Pharmaceutical Industries Ltd.	Solid state forms of sorafenib besylate, and processes for preparations thereof
EP2559431A1 (en)	2011-08-17	2013-02-20	Ratiopharm GmbH	Pharmaceutical composition comprising 4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methyl-pyridine-2-carboxamide
CN103664771B (zh) *	2012-09-19	2016-03-30	齐鲁制药有限公司	索拉非尼的晶型a及其制备方法
WO2014118807A1 (en) *	2013-02-04	2014-08-07	Intas Pharmaceuticals Limited	A novel process for the preparation of sorafenib tosylate form iii
CN104710354A (zh) *	2013-12-13	2015-06-17	江苏豪森药业股份有限公司	高纯度索拉非尼的制备方法
CN104761492A (zh) *	2014-01-03	2015-07-08	正大天晴药业集团股份有限公司	对甲苯磺酸索拉非尼的晶型及其制备方法
CN104177292A (zh) *	2014-08-08	2014-12-03	亿腾药业（泰州）有限公司	一种工业化生产甲苯磺酸索拉非尼多晶型ⅰ的方法
CN105439947A (zh) *	2014-12-01	2016-03-30	石药集团中奇制药技术（石家庄）有限公司	一种甲苯磺酸索拉非尼新晶型及其制备方法
EP3109236B1 (en)	2015-06-23	2017-08-09	F.I.S.- Fabbrica Italiana Sintetici S.p.A.	Scalable process for the preparation of sorafenib tosylate ethanol solvate and sorafenib tosylate form iii
CN105181844A (zh) *	2015-09-11	2015-12-23	江苏嘉逸医药有限公司	一种高效液相色谱法测定甲苯磺酸索拉非尼含量和有关物质的方法
CN105585523A (zh) *	2015-12-29	2016-05-18	上海北卡医药技术有限公司	一种对甲苯磺酸索拉非尼的新晶型及其制备方法和用途
CN107840823B (zh) *	2016-09-20	2021-08-17	意大利合成制造有限公司	用于制备甲苯磺酸索拉非尼乙醇溶剂化物和iii型甲苯磺酸索拉非尼的可变规模的方法
CN107915676A (zh) *	2017-10-26	2018-04-17	魏海霞	索拉非尼的制备方法
CN109796400B (zh) *	2017-11-16	2022-07-29	四川科伦药物研究院有限公司	一种甲苯磺酸索拉菲尼晶型及其制备方法
CN113773249A (zh) *	2020-06-10	2021-12-10	杭州中美华东制药有限公司	索拉非尼游离碱晶型Form X及其制备方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
LU86960A1 (fr) *	1987-07-31	1989-03-08	Oreal	Procede de preparation de piperidino-6 diamino-2,4 pyrimidine oxyde-3 et composes nouveaux
JPH02934A (ja) *	1988-05-27	1990-01-05	Konica Corp	非線形光学材料
JP2971291B2 (ja) *	1993-06-02	1999-11-02	田辺製薬株式会社	光学活性２−アミノ酪酸の製法
JP3866323B2 (ja) *	1996-03-27	2007-01-10	ポーラ化成工業株式会社	新規ｎ−ベンジルベンズアミド誘導体
JPH09316069A (ja) *	1996-03-28	1997-12-09	Ajinomoto Co Inc	新規キサントン誘導体
EP1140840B1 (en)	1999-01-13	2006-03-22	Bayer Pharmaceuticals Corp.	-g(v)-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
US8124630B2 (en)	1999-01-13	2012-02-28	Bayer Healthcare Llc	ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
EE04913B1 (et) *	1999-01-13	2007-10-15	Bayer Corporation	Omega-karboksarlasendatud difenlkarbamiidid kui RAF-kinaasi inhibiitorid ja neid sisaldavad farmatseutilised kompositsioonid
GB2367816A (en) *	2000-10-09	2002-04-17	Bayer Ag	Urea- and thiourea-containing derivatives of beta-amino acids
DK1450799T5 (da)	2001-12-03	2007-09-17	Bayer Pharmaceuticals Corp	Arulurinstofforbindelser sammen med andre cytostatiske eller cytotoksiske midler til behandling af humane cancere
US20030207872A1 (en) *	2002-01-11	2003-11-06	Bayer Corporation	Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
DE10203086A1 (de) *	2002-01-28	2003-07-31	Bayer Ag	5-Ring Heterozyklen
US7838541B2 (en) *	2002-02-11	2010-11-23	Bayer Healthcare, Llc	Aryl ureas with angiogenesis inhibiting activity
KR20050087776A (ko) *	2002-08-13	2005-08-31	산도즈 아게	세프디니르 중간체
US7166722B2 (en) *	2002-10-21	2007-01-23	Kirin Beer Kabushiki Kaisha	N-{2-chloro-4-[(6,7-dimethoxy-4-quinolyl)oxy]phenyl}-n′-(5-methyl-3-isoxazolyl)urea salt in crystalline form
PT1626714E (pt) *	2003-05-20	2007-08-24	Bayer Pharmaceuticals Corp	Diarilureias para doenças mediadas por pdgfr
NZ554119A (en)	2004-09-29	2010-07-30	Bayer Schering Pharma Ag	Process for the preparation of 4-{4-[({[4-chloro-3-(trifluoromethyl)phenyl]amino}carbonyl)amino]phenoxy}-N-methylpyridine-2-carboxamide

2005
- 2005-09-20 NZ NZ554119A patent/NZ554119A/en unknown
- 2005-09-20 ES ES05794785.5T patent/ES2532377T3/es active Active
- 2005-09-20 AU AU2005289099A patent/AU2005289099B2/en active Active
- 2005-09-20 PL PL05794785T patent/PL1797037T3/pl unknown
- 2005-09-20 BR BRPI0515944-0A patent/BRPI0515944B1/pt active IP Right Grant
- 2005-09-20 KR KR1020077009652A patent/KR101263032B1/ko active IP Right Grant
- 2005-09-20 UA UAA200704750A patent/UA90691C2/ru unknown
- 2005-09-20 SG SG200906449-4A patent/SG155997A1/en unknown
- 2005-09-20 SI SI200531947T patent/SI1797037T1/sl unknown
- 2005-09-20 CN CN2005800373684A patent/CN101052619B/zh active Active
- 2005-09-20 CA CA2581835A patent/CA2581835C/en active Active
- 2005-09-20 PT PT05794785T patent/PT1797037E/pt unknown
- 2005-09-20 EP EP05794785.5A patent/EP1797037B1/en active Active
- 2005-09-20 DK DK05794785T patent/DK1797037T3/en active
- 2005-09-20 US US11/664,332 patent/US8124782B2/en active Active
- 2005-09-20 JP JP2007533904A patent/JP2008514657A/ja active Pending
- 2005-09-20 WO PCT/EP2005/010118 patent/WO2006034796A1/en active Application Filing
- 2005-09-23 DO DO2005000183A patent/DOP2005000183A/es unknown
- 2005-09-26 AR ARP050104020A patent/AR053973A1/es active IP Right Grant
- 2005-09-27 MY MYPI20054553A patent/MY149873A/en unknown
- 2005-09-28 GT GT200500269A patent/GT200500269A/es unknown
- 2005-09-28 PE PE2009000510A patent/PE20091585A1/es active IP Right Grant
- 2005-09-28 PE PE2009000509A patent/PE20091584A1/es active IP Right Grant
- 2005-09-28 TW TW094133620A patent/TWI382973B/zh active
- 2005-09-28 PE PE2009000512A patent/PE20091587A1/es active IP Right Grant
- 2005-09-28 PE PE2009000511A patent/PE20091586A1/es not_active Application Discontinuation
- 2005-09-28 PE PE2005001144A patent/PE20060825A1/es active IP Right Grant
- 2005-09-28 UY UY29143A patent/UY29143A1/es active IP Right Grant
- 2005-09-29 SV SV2005002243A patent/SV2006002243A/es active IP Right Grant
- 2005-10-04 HN HN2005000768A patent/HN2005000768A/es unknown
2007
- 2007-03-20 IL IL182046A patent/IL182046A0/en active IP Right Grant
- 2007-03-26 CU CU20070069A patent/CU23754B7/es active IP Right Grant
- 2007-03-27 ZA ZA200702511A patent/ZA200702511B/en unknown
- 2007-03-28 EC EC2007007357A patent/ECSP077357A/es unknown
- 2007-03-30 MA MA29788A patent/MA28883B1/fr unknown
- 2007-04-26 NO NO20072173A patent/NO339647B1/no unknown
2008
- 2008-04-01 HK HK08103596.4A patent/HK1113484A1/xx unknown
2012
- 2012-11-02 JP JP2012242831A patent/JP5583190B2/ja active Active
2015
- 2015-03-16 HR HRP20150295TT patent/HRP20150295T1/hr unknown
- 2015-03-17 CY CY20151100268T patent/CY1116126T1/el unknown

Also Published As

Publication number	Publication date
PE20091585A1 (es)	2009-10-31
AU2005289099B2 (en)	2012-07-19
SV2006002243A (es)	2006-10-13
PE20091584A1 (es)	2009-10-28
HRP20150295T1 (hr)	2015-05-22
CA2581835C (en)	2012-12-18
BRPI0515944B1 (pt)	2021-11-09
PE20091587A1 (es)	2009-11-05
CN101052619A (zh)	2007-10-10
CU20070069A7 (es)	2010-11-27
GT200500269A (es)	2006-05-11
PE20091586A1 (es)	2009-10-31
MA28883B1 (fr)	2007-09-03
TW200626551A (en)	2006-08-01
TWI382973B (zh)	2013-01-21
SI1797037T1 (sl)	2015-06-30
DK1797037T3 (en)	2015-03-30
WO2006034796A1 (en)	2006-04-06
JP2013067625A (ja)	2013-04-18
JP2008514657A (ja)	2008-05-08
US8124782B2 (en)	2012-02-28
AU2005289099A1 (en)	2006-04-06
HN2005000768A (es)	2010-09-17
HK1113484A1 (en)	2008-10-03
KR20070058676A (ko)	2007-06-08
MY149873A (en)	2013-10-31
UY29143A1 (es)	2006-04-28
NO20072173L (no)	2007-06-14
NO339647B1 (no)	2017-01-16
ES2532377T3 (es)	2015-03-26
NZ554119A (en)	2010-07-30
US20080262236A1 (en)	2008-10-23
JP5583190B2 (ja)	2014-09-03
EP1797037A1 (en)	2007-06-20
CN101052619B (zh)	2012-02-22
SG155997A1 (en)	2009-10-29
IL182046A0 (en)	2007-07-24
CY1116126T1 (el)	2017-02-08
DOP2005000183A (es)	2006-03-31
CU23754B7 (es)	2012-01-31
PE20060825A1 (es)	2006-10-20
EP1797037B1 (en)	2014-12-17
ECSP077357A (es)	2007-04-26
UA90691C2 (en)	2010-05-25
AR053973A1 (es)	2007-05-30
CA2581835A1 (en)	2006-04-06
PT1797037E (pt)	2015-03-17
BRPI0515944A (pt)	2008-08-12
KR101263032B1 (ko)	2013-05-09
ZA200702511B (en)	2008-07-30

Publication	Publication Date	Title
PL1797037T3 (pl)	2015-07-31	Sposób otrzymywania 4-{4-[({[4-chloro-3-(trifluorometylo)-fenylo]amino}karbonylo)amino]fenoksy}-N-metylopirydyno-2-karboksyamidu
PL2097381T3 (pl)	2013-11-29	Jednowodzian 4-[4-({[4-chloro-3-(trifluorometylo)fenylo)]karbamoilo}amino)-3-fluorofenoksy]-N-metylopirydyno-2-karboksyamidu
TWI370131B (en)	2012-08-11	New hydrates and polymorphs of 4-[[(7r)-8-cyclopentyl-7-ethyl-5,6,7,8-tetrahydro-5-methyl-6-oxo-2-pteridinyl]amino]-3-mithoxy-n-(1-methyl-4-piperidinyl)-benzamide, process for their manufacture and their use as medicament
ZA200509103B (en)	2006-09-27	Process and intermediates for the preparation of 3-(amino)-3-cyclobutylmethyl-2-hydroxy-propionamideor salts thereof
IL192241A (en)	2014-01-30	A process for making 4 - (benzimidazolylmethylamino) - benzamides and their salts
SI1651622T1 (sl)	2007-06-30	Postopek za pripravo 2-(kinoksalin-5-ilsulfonilamino)-benzamidnih spojin
IL181169A0 (en)	2007-07-04	Trifluoromethyl substituted benzamides as kinase inhibitors
ZA200801854B (en)	2009-08-26	Method of preparing esomeprazole and salts thereof
IL182095A0 (en)	2007-07-24	Process for making phenoxy benzamide compounds
EP2070935A4 (en)	2011-06-29	NOVEL COMPOUND, COMPOSITION COMPRISING SAME, AND PROCESS FOR PRODUCING POLYMERIZABLE AMIDE
PL1835816T3 (pl)	2013-06-28	Sposób wytwarzania hydrolizatów białkowych
PT1753720E (pt)	2014-08-04	Processo para a preparação de perindopril e sais do mesmo
IL183597A0 (en)	2007-09-20	Manufacture process of n-substituted salicylamides
IL172169A0 (en)	2009-02-11	Processes for preparing (2s) - 3 - (4 - {2 - [amino] - 2 - oxoethoxy}
IL183366A0 (en)	2007-09-20	Manufacture process of n-substituted salicylamides
IL173887A0 (en)	2006-07-05	A process for the preparation of cilostazol and of the intermediates thereof
IL182277A0 (en)	2007-07-24	Method and intermediates for the preparation of derivatives of n-(1-benzhydryl-azetidin-3-yl)-n-phenyl-methylsulphonamide
AU2003235814A8 (en)	2003-07-24	Novel process for the preparation of trans-3- ethyl-2,5- dihydro-4- methyl-n-(2-( 4-(((((4-methyl cyclohexyl) amino)carbonyl) amino)sulfonyl) phenyl)ethyl) -2-oxo-1h-pyrrole -1-carboxamide
IL182445A0 (en)	2007-07-24	Process for the preparation of n-(3,5-dichloropyrid-4-yl)-4difluoromethoxy-8-methanesulfona mido-dibenzo[b,d]furan-1-caboxamide
IL165895A0 (en)	2006-01-15	Process for the preparation of phenyl pyrazole compounds
PL375250A1 (pl)	2006-11-27	Nowe N-[2-(alkoksykarbonylo) etylo]-N-alkilo-1-amino-1-dezoksy-D-glucitole i sposób ich wytwarzania
TWI320407B (en)	2010-02-11	Method for preparing n-(trifluoromethyl substituted phenyl) maleimides
IL180999A0 (en)	2007-07-04	Azo compounds and process for production thereof
PL377984A1 (pl)	2007-05-14	Sposób wytwarzania N-(5-amino-2-metylofenylo)-4-(3-pirydylo)-2-pirymidynoaminy
ZA200702609B (en)	2008-11-26	Process for making phenoxy benzamide compounds